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Abstract
Untreated opiate addiction remains a major health care crisis in New York and in most other urban
centers in America. Optimism for closing the gap between need and demand for treatment and its
availability has greeted the recent approval of a new opiate medication for addiction,
buprenorphine – which unlike methadone may be prescribed by independent, office-based
practitioners. The likelihood of buprenorphine fulfilling its potential is assessed in the light of the
massive expansion of methadone treatment more than 30 years earlier. It is concluded that the key,
indispensable ingredient of success will be true commitment on the part of Government to provide
care to all those who need it.
Over thirty years ago an editorial appeared in The New
York Times under the headline, "A Drug Success." [1] The
focus was the New York City Health Department's Metha-
done Maintenance Treatment Program, which had
expanded "so swiftly and so successfully...that there no
longer are waiting lists for admission..." Recently, another
medication – buprenorphine – was approved for treating
opiate addiction, [2] and there is hope that it will allow
many more patients to receive help. Critical to significant
expansion of treatment capacity will be "clinician atti-
tudes and the extent to which they embrace buprenor-
phine . . ." [3] However, to gauge the degree to which
buprenorphine's potential will be realized it is important
to consider the factors that went into the success of meth-
adone in the early 70s.
New treatment services were being established through-
out the country in those days, but the most dramatic
increase took place in New York City, and it was due first
and foremost to the vision and commitment of one man,
Gordon Chase, the City's Health Services Administrator
under then-Mayor John Lindsay. (Chase died in an auto
accident in 1980 at the age of 47.) Chase, who had only a
bachelor's degree and had never worked in the field of
health care, was determined that every single heroin user
would be offered prompt access to treatment; to achieve
this goal he concluded that methadone maintenance
would have to be the cornerstone of the City's efforts. He
acknowledged readily that he knew very little about meth-
adone (few at the time knew more – methadone had been
introduced just five years before [4]); he had been per-
suaded, however, that without methadone the vast major-
ity of those who needed and were willing to accept help
would be abandoned.
Chase peremptorily dismissed the litany of reasons staff
gave in urging him to "go slow": rapid expansion of meth-
adone treatment had never been attempted, and could be
a widely publicized disaster that would undermine treat-
ment efforts everywhere; individualization of care and
"comprehensive ancillary services" were considered indis-
pensable components of treatment and required extensive
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time and staff training to establish; etc. Indeed, virtually
every experienced professional in the country rejected the
very concept of expansion on a massive scale. This may
explain why Chase asked the author to implement his
vision of "treatment on request" for all addicts; I was a res-
ident in Public Health at the time, whose only prior med-
ical training had consisted of two years of general surgery,
and whose administrative background was limited to a
few months directing the New York City component of a
national nutrition survey.
The consistent response by Chase to the nay-sayers within
and outside City Government was to ask: "How convinc-
ing will your concerns and criticisms be to parents whose
children sought help but were turned away, and subse-
quently died of an overdose?" His argument was compel-
ling,. In any event, Chase prevailed and within two years
the City Health Department had established a program
with an active enrollment of approximately 11,000! Con-
comitantly, the Health Department spurred ("shamed" is
probably a more accurate term) other methadone and
drug-free providers in New York and elsewhere to increase
their own capacity markedly.
The net result for the City of New York was dramatic: a
sharp reduction in addiction-related property crime, drug
arrests, hepatitis and deaths attributed to drug depend-
ence. [5] As for the Health Department's new methadone
program in particular, whether measured by retention
rates, employment, drug use, health status or any other
parameter, the extensively documented outcomes were
every bit as good as those of other addiction treatment
services. [6]
The New York City Health Department program was
financed entirely by City and State funds and by Medicaid
reimbursement for eligible patients. The Federal Govern-
ment provided neither fiscal nor moral support for the
City's unprecedented response to opiate addiction, the
most important clinical and public health challenge of the
day. As for the rest of the country, without the demonstra-
tion by New York that massive, rapid expansion was feasi-
ble, it is likely that things would have proceeded at a
snail's pace.
Tragically, since the mid-70s there has been little if any
further increase in addiction treatment capacity of any
kind in America. Roughly the same 20 percent of the esti-
mated heroin addicted population receives care today as
did then – before the onset of AIDS. [7] Undoubtedly the
greatest obstacle to accommodating more patients has
been the absolute monopoly on methadone maintenance
that has been given to "programs;" independent, office-
based practitioners are excluded from the field by law – a
restriction on prescribing that applies to no other medica-
tion in the US pharmacopoeia.
A "new" treatment option
The New York Times recently reported [8] that an estimated
36,000 patients receive methadone in the City – essen-
tially the same number as three decades ago (according to
one source, 34,000 patients were being treated with meth-
adone maintenance in 1974 [9]). At the same time, The
Times  noted optimistically that prescriptions for
buprenorphine are "expected to soar in the coming years"
(one year earlier the paper had run another optimistic
story on buprenorphine under the headline, "New drug
promises shift in treatment for heroin addicts" [10]). In
fact, however, if the past is prologue, the acceptance and
utilization of buprenorphine may be a long time coming.
As early as 1978 it had been described as a medication
with "a unique pharmacology with immediately obvious
therapeutic application as a maintenance drug in narcotic
addiction" [11]. And yet, to make this "immediately obvi-
ous" medication a reality " . . . took considerable financial
commitment from NIDA [National Institute on Drug
Abuse], more than two decades of dedicated effort by myr-
iad researchers and practitioners, and the collaboration of
a willing and savvy pharmaceutical manufacturer. It also
literally took an act of congress" [3].
The breakthrough itself, when it finally came, was not
pharmacological but regulatory. Unlike methadone,
buprenorphine could henceforth be prescribed for opiate
dependence by any physician who is "certified." Certifica-
tion requires nothing more than an application and dem-
onstration that the physician has completed an eight-hour
training course (which also is available on-line). While
the demands imposed on "methadone programs" are
undiminished, and office-based physicians continue to be
barred from making methadone available to their
patients, buprenorphine can be prescribed to a new
patient for a full month, and in some states (e.g., New
York) the prescription can be refillable without further
physician-patient contact for five additional months.
Surely not good medical practice – but in contrast to
methadone, not illegal! The one restriction that makes
treatment with buprenorphine exceptional is that no phy-
sician or group practice may treat more than 30 patients at
a time (this limit, as it applies to group practices, was
eliminated in a bill passed by Congress and signed by the
President in August, 2005 [12].
Despite all the hype, the ease of certification and the rela-
tive absence of regulatory constraints, there's little to cheer
about. Notwithstanding the very considerable effort of the
Federal Government, and the extensive advertising and
public relations campaign of buprenorphine's manufac-
turer, the percent of previously untreated opiate-depend-Publish with BioMed Central    and   every 
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ent individuals that receives this medication appears to be
miniscule. Worse, it's by no means clear that anyone cares;
no Federal targets have been announced, and no one
seems to be measuring the increment in patient numbers
(and if they are, they are not talking, which also bodes ill).
Of course, it is likely that the manufacturer is following its
sales very, very closely, but it too has released no data.
One major barrier to significant expansion of addiction
treatment with buprenorphine is the persistent mixed
message sent by Government. We can hardly expect phy-
sicians, patients or the public at large to embrace treat-
ment with one medication (buprenorphine), when
Government itself continues to reflect and reinforce the
stigma towards treatment with another medication
(methadone) for the same patients and the same disease.
We'll never see significant numbers of physicians – i.e.,
"mainstream medicine" – prescribe buprenorphine when
methadone must, by law, be associated with a fully pano-
ply of "comprehensive ancillary services," frequent urinal-
ysis, stringent restrictions on "take-home privileges," and
inspection and approval of all providers by "accreditation
agencies." In addition, of course, there continues to be an
absolute bar, regardless of circumstances, against treat-
ment with methadone by independent office-based prac-
titioners.
The experience three years after buprenorphine was
approved speaks for itself. Less than 500 prescriptions for
buprenorphine, from all sources, were written in New
York City during the month of June, 2005. [13] If each
prescription were for an unduplicated individual, the total
recipients of this medication would be one-quarter of one
percent of the estimated 200,000 untreated heroin-
dependent population of the city. [14]
Conclusion
We need Government to give strong, unqualified support
to the premise that addiction is a chronic medical condi-
tion. It must acknowledge forthrightly that neither
buprenorphine nor methadone nor any other treatment
modality, medication-based or drug-free, is a "cure." At
the same time, it must stress the fact that addiction is emi-
nently treatable. (The same reality of "treatable but not
curable" applies to all chronic illnesses.) Above all, how-
ever, we need leaders with the commitment, pragmatism
and common sense that Gordon Chase personified. Sadly,
such traits are rarely evidenced today by those who influ-
ence and implement policy – in government, academia or
the private sector. Meanwhile, hundreds of thousands of
opiate dependent people in New York and throughout the
country continue to suffer and die, and society at large
bears the associated fiscal and human costs. It is high time
to reconsider the rhetorical question Chase posed almost
35 years ago: Are our rationalizations for tolerating the
status quo truly persuasive? Would they be accepted by
those who are suffering and dying as a consequence of
inaction?
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